Targeted anticancer therapy: Overexpressed receptors and nanotechnology

Clinica Chimica Acta

Volumn 436, Issue , 2014, Pages 78-92

  Akhtar, Mohd Javed ^a   Ahamed, Maqusood ^a   Alhadlaq, Hisham A ^a,b   Alrokayan, Salman A ^a   Kumar, Sudhir ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF LUCKNOW   (India)

Author keywords

Anticancer drugs; Ligands; Nanoparticles; Overexpressed receptors; Tumor microenvironment

Indexed keywords

ALPHA3 INTEGRIN; ANTINEOPLASTIC AGENT; BOMBESIN RECEPTOR; CAMPTOTHECIN; CD71 ANTIGEN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FOLATE RECEPTOR; FOLATE RECEPTOR 1; FOLATE RECEPTOR 2; FOLATE RECEPTOR GAMMA; G PROTEIN COUPLED RECEPTOR; GEMCITABINE; METHOTREXATE; NANOCARRIER; NEUROMEDIN B; PACLITAXEL; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR; SOMATOSTATIN RECEPTOR; TRANSFERRIN RECEPTOR 2; UNCLASSIFIED DRUG; VEDOTIN; RECEPTORS, CELL SURFACE;

CANCER CELL; CANCER TISSUE; CONCENTRATION (PARAMETERS); DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG EFFECTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METABOLISM; METHODS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NANOTECHNOLOGY; NEOPLASMS; RECEPTORS, CELL SURFACE;

EID: 84901393987     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.05.004     Document Type: Review

References (199)

1. Boyle P., Levin B. World Cancer Report 2008, International Agency for Research on Cancer Press, Lyon, France.
2. Sutcliffe S.B. Cancer control: life and death in an unequal world. Curr Oncol 2012, 19:12-15.
3. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
4. Iyer A.K., Greish K., Fang J., et al. Exploiting the enhanced permeability and retention effect for tumour targeting. Drug Discov Today 2006, 11:812-818.
5. Maeda H. Tumour-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010, 21:797-802.
6. Lee E.S., Bae Y.H.J. Recent progress in tumour pH targeting nanotechnology. J Control Release 2008, 132:164-170.
7. Wei H., Zhang X.Z., Chen W.Q., et al. Self-assembled thermo sensitive micelles based on poly(l-lactide-star block-N-isopropyl acrylamide) for drug delivery. J Biomed Mater Res 2007, 83:980-989.
8. Wei H., Zhang X., Cheng C., et al. Self-assembled, thermosensitive micelles of a star block copolymer based on PMMA and PNIPAAm for controlled drug delivery. Biomaterials 2007, 28:99-107.
9. Saito G., Swanson J.A., Lee K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003, 55:199-215.
10. Rapoport N.Y., Christensen D.A., Fain H.D., et al. Ultrasound-triggered drug targeting of tumours in vitro and in vivo. Ultrasonics 2004, 42:943-950.
11. Han G., You C.C., Kim B.J., et al. Light regulated release of DNA and its delivery to nuclei by means of photolabile gold nanoparticles. Angew Chem Int Ed Engl 2006, 45:3165-3169.
12. Mura S., Nicolas J., Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater 2013, 12:991-1003.
13. Schroeder A., Heller D.A., Winslow M.M., et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012, 12:39-50.
14. Zwanziger D., Beck-Sickinger A.G. Radiometal targeted tumour diagnosis and therapy with peptide hormones. Curr Pharm Des 2008, 14:2385-2400.
15. Wettschureck N., Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev 2005, 85:1159-1204.
16. Oldham W.M., Hamm H.E. How do receptors activate G proteins?. Adv Protein Chem 2007, 74:67-93.
17. Jensen R.T., Battey J.F., Spindel E.R., et al. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 2008, 60:1-42.
18. Sancho V., Di Florio A., Moody T.W., et al. Bombesin receptor mediated imaging and cytotoxicity: review and current status. Curr Drug Deliv 2011, 8:79-134.
19. Fathi Z., Corjay M.H., Shapira H., et al. BRS-3: novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem 1993, 268:5979-5984.
20. Gonzalez N., Moody T.W., Igarashi H., et al. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes 2008, 15:58-64.
21. Weber H.C. Regulation and signaling of human bombesin receptors and their biological effects. Curr Opin Endocrinol Diabetes Obes 2009, 16:66-71.
22. Majumdar I.D., Weber H.C. Biology of mammalian bombesin-like peptides and their receptors. Curr Opin Endocrinol Diabetes Obes 2011, 18:68-74.
23. Engel J.B., Keller G., Schally A.V., et al. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215. Clin Cancer Res 2005, 11:2408-2415.
24. Moody T.W., Sun L.C., Mantey S.A., et al. In vitro and in vivo antitumour effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharmacol Exp Ther 2006, 318:1265-1272.
25. Safavy A., Raisch K.P., Matusiak D., et al. Single-drug multiligand conjugates: synthesis and preliminary cytotoxicity evaluation of a paclitaxel-dipeptide "scorpion" molecule. Bioconjug Chem 2006, 17:565-570.
26. Accardo A., Salsano G., Morisco A., et al. Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent. Int J Nanomedicine 2012, 7:2007-2017.
27. Accardo A., Mansi R., Morisco A., et al. Peptide modified nanocarriers for selective targeting of bombesin receptors. Mol Biosyst 2010, 6. [878-7].
28. 64Cu-labeled bombesin analogue. Bioconjug Chem 2003, 14:756-763.
29. Smith C.J., Volkert W.A., Hoffman T.J. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 2005, 32:733-740.
30. Parry J.J., Kelly T.S., Andrews R., et al. In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem 2007, 18:1110-1117.
31. Yang H., Cai H., Wan L., et al. Bombesin analogue-mediated delivery preferentially enhances the cytotoxicity of a mitochondria-disrupting peptide in tumour cells. PLoS One 2013, 8:e57358.
32. Herlin G., Kolbeck K.G., Menzel P.L., et al. Quantitative assessment of 99mTc-depreotide uptake in patients with nonsmall-cell lung cancer: immunohistochemical correlations. Acta Radiol 2009, 50:902-908.
33. Sclafani F., Carnaghi C., Di Tommaso L., et al. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumours. Tumori 2011, 97:620-628.
34. Mazzucchelli R., Morichetti D., Santinelli A., et al. Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. Anal Cell Pathol (Amst) 2010, 33:27-36.
35. He Y., Yuan X.M., Lei P., et al. The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells. Acta Pharmacol Sin 2009, 30:1053-1059.
36. He S.W., Shen K.Q., He Y.J., et al. Regulatory effect and mechanism of gastrin and its antagonists on colorectal carcinoma. World J Gastroenterol 1999, 5:408-416.
37. Hu C., Yi C., Hao Z., et al. The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells. Cancer Biol Ther 2004, 3:726-730.
38. Ji X.Q., Ruan X.J., Chen H., et al. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Med Sci Monit 2011, 17:RA169-RA176.
39. Guillermet-Guibert J., Lahlou H., Cordelier P., et al. Physiology of somatostatin receptors. J Endocrinol Invest 2005, 28:5-9.
40. Mariniello B., Finco I., Sartorato P., et al. Somatostatin receptor expression in adrenocortical tumours and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells. J Endocrinol Invest 2011, 34:e131-e138.
41. Klagge A., Krause K., Schierle K., et al. Somatostatin receptor subtype expression in human thyroid tumours. Horm Metab Res 2010, 42:237-240.
42. Sun L.C., Coy D.H. Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv 2011, 8:2-10.
43. Huang C.M., Wu Y.T., Chen S.T. Targeting delivery of paclitaxel into tumour cells via somatostatin receptor endocytosis. Chem Biol 2000, 7:453-461.
44. Shen H., Hu D., Du J., et al. Paclitaxel-octreotide conjugates in tumour growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice. Eur J Pharmacol 2008, 601:23-29.
45. Sun M., Wang Y., Shen J., et al. Octreotide-modification enhances the delivery and targeting of DOX-loaded liposomes to somatostatin receptors expressing tumour in vitro and in vivo. Nanotechnology 2010, 21:475101.
46. Zhang J., Jin W., Wang X., et al. A novel octreotide modified lipid vesicle improved the anticancer efficacy of DOX in somatostatin receptor 2 positive tumour models. Mol Pharm 2010, 7:1159-1168.
47. Huo M., Zou A., Yao C., et al. Somatostatin receptor-mediated tumour-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials 2012, 33:6393-6407.
48. Franko-Tobin L.G., Mackey L.V., Huang W., et al. Notch1-mediated tumour suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics. Oncologist 2012, 17:220-232.
49. Bagnato A., Tecce R., Moretti C., et al. Autocrine actions of endothelin 1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1995, 1:1059-1066.
50. Levin E.R. Endothelins. N Engl J Med 1995, 333:356-363.
51. Masaki T. The endothelin family: an overview. J Cardiovasc Pharmacol 2000, 35:S3-S5.
52. Nelson J., Bagnato A., Battistini B., et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003, 3:110-116.
53. Bittner M., Meltzer P., Chen Y., et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (London) 2000, 406:536-540.
54. Ross D.T., Scherf U., Eisen M.B., et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24:227-235.
55. Raymond M.N., Robin P., De Zen F., et al. Differential endothelin receptor expression and function in rat myometrial cells and leiomyoma ELT3 cells. Endocrinology 2009, 150:4766-4776.
56. Asundi J., Reed C., Arca J., et al. An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma. Clin Cancer Res 2011, 17:965-975.
57. Chen X., Plasencia C., Hou Y., et al. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem 2005, 48:1098-1106.
58. Cai W., Niu G., Chen X. Imaging of integrins as biomarkers for tumour angiogenesis. Curr Pharm Des 2008, 14:2943-2973.
59. Mizejewski G.J. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999, 222:124-138.
60. Humphries J.D., Byron A., Humphries M.J. Integrin ligands at a glance. J Cell Sci 2006, 119:3901-3903.
61. Pytela R., Pierschbacher M.D., Ruoslahti E. Identification and isolation of a 140kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell 1985, 40:191-198.
62. Berrier A.L., Yamada K.M. Cell-matrix adhesion. J Cell Physiol 2007, 213. [565-3].
63. Guo W., Giancotti F.G. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004, 5:816-826.
64. Mitra S.K., Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006, 18:516-523.
65. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
66. Kren A., Baeriswyl V., Lehembre F., et al. Increased tumour cell dissemination and cellular senescence in the absence of β1-integrin function. EMBO J 2007, 26:2832-2842.
67. Murphy E.A., Majeti B.K., Barnes L.A., et al. Nanoparticle-mediated drug delivery to tumour vasculature suppresses metastasis. Proc Natl Acad Sci U S A 2008, 105:9343-9348.
68. Chen K., Xie J., Xu H., et al. Triblock copolymer coated iron oxide nanoparticle conjugate for tumour integrin targeting. Biomaterials 2009, 30:6912-6919.
69. Zhan C., Gu B., Xie C., et al. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release 2010, 143:136-142.
70. Jiang X., Sha X., Xin H., et al. Self-aggregated PEGylated poly(trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumours. Biomaterials 2011, 32:9457-9469.
71. Aina O.H., Marik J., Gandour-Edwards R., et al. Near-infrared optical imaging of ovarian cancer xenografts with novel alpha 3-integrin binding peptide "OA02". Mol Imaging 2005, 4. [439-7].
72. Xiao K., Li Y., Lee J.S., et al. OA02 peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res 2012, 72:2100-2110.
73. Cummings J., Mcardle C.S. Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. Br J Cancer 1986, 53:835-838.
74. Sudimack J., Lee R.J. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000, 41:147-162.
75. Yoo H., Park T. Folate-receptor-targeted delivery of DOX nano-aggregates stabilized by DOX-PEG-folate conjugate. J Control Release 2004, 100:247-256.
76. Shia J., Klimstra D.S., Nitzkorski J.R., et al. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol 2008, 39:498-505.
77. Matsue H., Rothberg K.G., Takashima A., et al. Folate receptor allows cells to grow in low concentrations of 5-methyltetrahydrofolate. Proc Natl Acad Sci U S A 1992, 89:6006-6009.
78. Kelemen L.E. The role of folate receptor α in cancer development, progression and treatment: cause, consequence or innocent bystander?. Int J Cancer 2006, 119:243-250.
79. Mcguire J.J. Anticancer antifolates: current status and future directions. Curr Pharm Des 2003, 9:2593-2613.
80. Deng Y., Zhou X., Kugel Desmoulin S., et al. Synthesis and biological activity of a novel series of 6-substituted thieno 2,3d-pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry. J Med Chem 2009, 52:2940-2951.
81. Leamon C.P., Reddy J.A. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004, 56:1127-1141.
82. Leamon C.P., Reddy J.A., Vlahov I.R., et al. Preclinical antitumour activity of a novel folate-targeted dual drug conjugate. Mol Pharm 2007, 4:659-667.
83. Reddy J.A., Dorton R., Westrick E., et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007, 67:4434-4442.
84. Paulos C.M., Reddy J.A., Leamon C.P., et al. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol 2004, 66:1406-1414.
85. Chen C., Ke J., Zhou X.E., et al. Structural basis for molecular recognition of folic acid by folate receptors. Nature 2013, 500:486-489.
86. Parker N., Turk M.J., Westrick E., et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005, 338:284-293.
87. Muller C., Schibli R. Folic acid conjugates for nuclear imaging of folate receptor-positive cancer. J Nucl Med 2011, 52:1-4.
88. Low P.S., Henne W.A., Doorneweerd D.D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008, 41:120-129.
89. Zhao X., Li H., Lee R.J. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 2008, 5:309-319.
90. Mansoori A., Brandenburg K., Shakeri-Zadeth A. A comparative study of two folate-conjugated gold nanoparticles for cancer nanotechnology applications. Cancer 2010, 2:1911-1928.
91. Liu X., Ma S., Dai C., et al. Antiproliferative, antiinvasive, and proapoptotic activity of folate receptor α-targeted liposomal DOX in nonfunctional pituitary adenoma cells. Endocrinology 2013, 154:1414-1423.
92. Pan J., Feng S.S. Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials 2008, 29:2663-2672.
93. Pan J., Feng S.S. Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)-loaded nanoparticles of biodegradable polymers. Biomaterials 2009, 30:1176-1183.
94. Prabaharan M., Grailer J.J., Pilla S., et al. Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn(r) H40, poly (l-lactide) and poly(ethylene glycol) for tumour targeted drug delivery. Biomaterials 2009, 30:3009-3019.
95. Gabizon A., Tzemach D., Gorin J., et al. Improved therapeutic activity of folate-targeted liposomal DOX in folate receptor-expressing tumour models. Cancer Chemother Pharmacol 2010, 66:43-52.
96. Wang J., Liu W., Tu Q., et al. Folate-decorated hybrid polymeric nanoparticles for chemically and physically combined paclitaxel loading and targeted delivery. Biomacromolecules 2011, 12:228-234.
97. Riviere K., Huang Z., Jerger K., et al. Antitumour effect of folate-targeted liposomal DOX in KB tumour-bearing mice after intravenous administration. J Drug Target 2011, 19:14-24.
98. Singh M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr Pharm Des 1999, 5:443-451.
99. Vyas S.P., Sihorkar V. Endogenous carriers and ligands in non-immunogenic site-specific drug delivery. Adv Drug Deliv Rev 2000, 43:101-164.
100. Kircheis R., Wightman L., Kursa M., et al. Tumour targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment. Gene Ther 2002, 9:731-735.
101. Inoue T., Cavanaugh P.G., Steck P.A., et al. Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 1993, 156:212-217.
102. Qian Z.M., Li H., Sun H., et al. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002, 54:561-587.
103. Yoon D.J., Kwan B.H., Chao F.C., et al. Intratumoural therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery. Cancer Res 2010, 70:4520-4527.
104. Daniels T.R., Bernabeu E., Rodríguez J.A., et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 1820, 2012:291-317.
105. Habeshaw J.A., Lister T.A., Stansfeld A.G., et al. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet 1983, 1:498-501.
106. Seymour G.J., Walsh M.D., Lavin M.F., et al. Transferrin receptor expression by human bladder transitional cell carcinomas. Urol Res 1987, 15:341-344.
107. Prior R., Reifenberger G., Wechsler W. Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction. Virchows Arch A Pathol Anat Histopathol 1990, 416:491-496.
108. Kondo K., Noguchi M., Mukai K., et al. Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis. Chest 1990, 97:1367-1371.
109. Yang D.C., Wang F., Elliott R.L., et al. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. Anticancer Res 2001, 21:541-549.
110. Recht L., Torres C.O., Smith T.W., et al. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumour immunotherapy. J Neurosurg 1990, 72:941-945.
111. Chirasani S.R., Markovic D.S., Synowitz M., et al. Transferrin-receptor-mediated iron accumulation controls proliferation and glutamate release in glioma cells. J Mol Med 2009, 87:153-167.
112. Candolfi M., Kroeger K.M., Xiong W., et al. Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anticancer Agents Med Chem 2011, 11:729-738.
113. Dufès C. Al Robaian M, Somani S, Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Ther Deliv 2013, 4:629-640.
114. Ulbrich K., Hekmatara T., Herbert E., et al. Transferrin- and transferrin receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009, 71:251-256.
115. Ulbrich K., Knobloch T., Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target 2011, 19:125-132.
116. Jiang W., Xie H., Ghoorah D., et al. Conjugation of functionalized SPIONs with transferrin for targeting and imaging brain glial tumours in rat model. PLoS One 2012, 7:e37376.
117. Pirollo K.F., Zon G., Rait A., et al. Tumour-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006, 17:117-124.
118. Camp E.R., Wang C., Little E.C., et al. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther 2013, 20:222-228.
119. Salvati A., Pitek A.S., Monopoli M.P., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013, 8:137-143.
120. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
121. Blessing T., Kursa M., Holzhauser R., et al. Different strategies for formation of PEGylated EGF-conjugated PEI/DNA complexes for targeted gene delivery. Bioconjug Chem 2001, 12:529-537.
122. Linggi B., Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 2006, 16:649-656.
123. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006, 12:5268-5272.
124. Graus-Porta D., Beerli R.R., Daly J.M., et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16:1647-1655.
125. Citri A., Skaria K.B., Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003, 284:54-65.
126. Schlessinger J., Lemmon M.A. Nuclear signaling by receptor tyrosine kinase kinases: the first robin of spring. Cell 2006, 127:45-48.
127. Master A.M., Gupta A.S. EGF receptor-targeted nanocarriers for enhanced cancer treatment. Nanomedicine (Lond) 2012, 7:1895-1906.
128. Song S., Liu D., Peng J., et al. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J 2009, 23:1396-1404.
129. Taheri A., Dinarvand R., Atyabi F., et al. Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumour cells. Eur J Pharm Sci 2012, 47:331-340.
130. Engel R., Kaklaman V. HER2-positive breast cancer: current and future treatment strategies. Drugs 2007, 67:1329-1341.
131. Liu C.W., Lin W.J. Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for DOX. Int J Nanomedicine 2012, 7:4749-4767.
132. Han C.Y., Yue L.L., Tai L.Y., et al. A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro. Int J Nanomedicine 2013, 8:1541-1549.
133. Ai S., Jia T., Ai W., et al. Targeted delivery of DOX through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells. Br J Pharmacol 2013, 168:1719-1735.
134. Knights V., Cook S.J. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010, 125:105-117.
135. Wesche J., Haglund K., Haugsten E.M. Fibroblast growth factors and their receptors in cancer. Biochem J 2011, 437:199-213.
136. Mohammadi M., Olsen S.K., Ibrahimi O.A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005, 16:107-137.
137. Wang F., Kan M., Yan G., et al. Alternately spliced NH2-terminal immunoglobulin-like loop I in the ectodomain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1. J Biol Chem 1995, 270:10231-10235.
138. Haugsten E.M., Wiedlocha A., Olsnes S. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 2010, 8:1439-1452.
139. Heinzle C., Sutterlüty H., Grusch M., et al. Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. Expert Opin Ther Targets 2011, 15:829-846.
140. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10:116-129.
141. Xiao W., Chen X., Yang L., et al. Co-delivery of DOX and plasmid by a novel FGFR-mediated cationic liposome. Int J Pharm 2010, 393:119-126.
142. Wang X., Deng L., Chen X., et al. Truncated bFGF-mediated cationic liposomal paclitaxel for tumour-targeted drug delivery: improved pharmacokinetics and biodistribution in tumour-bearing mice. J Pharm Sci 2011, 100:1196-1205.
143. Cai L., Qiu N., Li X., et al. A novel truncated basic fibroblast growth factor fragment-conjugated poly(ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumour cells. Int J Pharm 2011, 408:173-182.
144. Cai L., Wang X., Wang W., et al. Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumour in vivo. Int J Nanomedicine 2012, 7:4499-4510.
145. Szlachcic A., Pala K., Zakrzewska M., et al. FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine 2012, 7:5915-5927.
146. John C.S., Vilner B.J., Geyer B.C., et al. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumours. Cancer Res 1999, 59:4578-4583.
147. Cobos E.J., Entrena J.M., Nieto F.R., et al. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol 2008, 6:344-366.
148. Maurice T., Su T.P. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009, 124:195-206.
149. Martins C.P., Brown-Swigart L., Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumours. Cell 2006, 127:1323-1334.
150. Su T.P. Evidence for sigma opioid receptor: binding of [3H] SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther 1982, 223:284-290.
151. Largent B.L., Gundlach A.L., Snyder S.H. Sigma receptors on NCB-20 hybrid neurotumour cells labeled with (+)[3H]SKF 10,047 and (+)[3H]3-PPP. Eur J Pharmacol 1986, 124:183-187.
152. Walker J.M., Bowen W.D., Walker F.O., et al. Sigma receptors: biology and function. Pharmacol Rev 1990, 42:355-402.
153. Hornick J.R., Spitzer D., Goedegebuure P., et al. Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. Surgery 2012, 152:S152-S156.
154. Hornick J.R., Xu J., Vangveravong S., et al. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol Cancer 2010, 9:298.
155. Hayashi T., Su T.P. Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc Natl Acad Sci U S A 2001, 98:491-496.
156. Hayashi T., Su T.P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007, 131:596-610.
157. Pal A., Fontanilla D., Gopalakrishnan A., et al. The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur J Pharmacol 2012, 682:12-20.
158. Weissman A.D., Su T.P., Hedreen J.C., et al. Sigma receptors in postmortem human brains. J Pharmacol Exp Ther 1988, 247:29-33.
159. Seth P., Ganapathy M.E., Conway S.J., et al. Expression pattern of the type 1 sigma receptor in the brain and identity of critical anionic amino acid residues in the ligand-binding domain of the receptor. Biochim Biophys Acta 2001, 1540:59-67.
160. Guitart X., Codony X., Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl) 2004, 174:301-319.
161. Walter L., Hajnoczky G. Mitochondria and endoplasmic reticulum: the lethal interorganelle cross-talk. J Bioenerg Biomembr 2005, 37:191-206.
162. Csordás G., Renken C., Várnai P., et al. Structural and functional features and significance of the physical linkage between ER and mitochondria. J Cell Biol 2006, 174:915-921.
163. Csordás G., Várnai P., Golenár T., et al. Imaging interorganelle contacts and local calcium dynamics at the ER-mitochondrial interface. Mol Cell 2010, 39:121-132.
164. Su T.P., London E.D., Jaffe J.H. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 1988, 240:219-221.
165. Ramachandran S., Chu U.B., Mavlyutov T.A., et al. The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids. Eur J Pharmacol 2009, 609:19-26.
166. Fontanilla D., Johannessen M., Hajipour A.R., et al. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009, 323:934-937.
167. Wu Z., Bowen W.D. Role of sigma-1 receptor C-terminal segment in inositol 1,4,5-trisphosphate receptor activation: constitutive enhancement of calcium signaling in MCF-7 tumour cells. J Biol Chem 2008, 283:28198-28215.
168. Ortega-Roldan J.L., Ossa F., Schnell J.R. Characterization of the human sigma-1 receptor chaperone domain structure and BiP interactions. J Biol Chem 2013, 288:21448-21457.
169. van Waarde A., Rybczynska A.A., Ramakrishnan N., et al. Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr Pharm Des 2010, 16:3519-3537.
170. Hou C., Tu Z., Mach R., et al. Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. Nucl Med Biol 2006, 33:203-209.
171. Zeng C., Vangveravong S., Xu J., et al. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res 2007, 67:6708-6716.
172. Kashiwagi H., Mcdunn J.E., Simon P.O., et al. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer 2007, 6:48.
173. Crawford K.W., Bowen W.D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumour cell lines. Cancer Res 2002, 62:313-322.
174. Spitzer D., Simon P.O., Kashiwagi H., et al. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling. Cancer Res 2012, 72:201-209.
175. Zhang Y., Huang Y., Zhang P., et al. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells. Int J Nanomedicine 2012, 7:4473-4485.
176. Wang Y., Xu J., Xia X., et al. SV119-gold nanocage conjugates: a new platform for targeting cancer cells via sigma-2 receptors. Nanoscale 2012, 4:421-424.
177. Agris P.F., Guenther R.H., Sierzputowska-Gracz H.E., et al. Solution structure of a synthetic peptide corresponding to a receptor binding region of FSH (hFSH-h 33-53). J Protein Chem 1992, 11:495-497.
178. Konishi I. Gonadotropins and ovarian carcinogenesis: a new era of basic research and its clinical implications. Int J Gynecol Cancer 2006, 16:16-22.
179. Minegishi T., Kameda T., Hirakawa T., et al. Expression of gonadotropin and activin receptor messenger ribonucleic acid in human ovarian epithelial neoplasms. Clin Cancer Res 2000, 6:2764-2770.
180. Wang J., Lin L., Parkash V., et al. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumours: a novel approach to explain the field effect of ovarian cancer development in secondary Mullerian systems. Int J Cancer 2003, 103:328-334.
181. Zhang X.Y., Chen J., Zheng Y.F., et al. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res 2009, 69:6506-6514.
182. Kim S.Y., Cho S.H., Lee Y.M., et al. Biotin-conjugated block copolymeric nanoparticles as tumour-targeted drug delivery systems. Macromol Res 2007, 15:646-655.
183. Chen S., Zhao X., Chen J., et al. Mechanism-based tumour-targeting drug delivery system validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug Chem 2010, 21:979-987.
184. Heo D.N., Yang D.H., Moon H.J., et al. Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy. Biomaterials 2012, 33:856-866.
185. Lepenies B., Yin J., Seeberger P.H. Applications of synthetic carbohydrates to chemical biology. Curr Opin Chem Biol 2010, 14:404-411.
186. Lepenies B., Seeberger P.H. The promise of glycomics, glycan arrays and carbohydrate-based vaccines. Immunopharmacol Immunotoxicol 2010, 32:196-207.
187. Lepenies B., Lee J., Sonkaria S. Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv Drug Deliv Rev 2013, 65:1271-1281.
188. Kooyk Y., Rabinovich G.A. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol 2008, 9:593-601.
189. Tang C.K., Sheng K.C., Apostolopoulos V., et al. Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors. Expert Rev Vaccines 2008, 7:1005-1018.
190. Sancho D., Reis E.S.C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol 2012, 30:491-529.
191. Sancho D., Reis E.S.C. Sensing of cell death by myeloid C-type lectin receptors. Curr Opin Immunol 2013, 25:46-52.
192. Cummings R.D., Mcever R.P. C-type lectins. Essentials of glycobiology 2009, Cold Spring Harbor, NY. A. Varki, R.D. Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. Bertozzi, G.W. Hart, M.E. Etzler (Eds.).
193. Hashida M., Nishikawa M., Yamashita F., et al. Cell-specific delivery of genes with glycosylated carriers. Adv Drug Deliv Rev 2001, 52:187-196.
194. Bernardes G.J., Kikkeri R., Maglinao M., et al. Design, synthesis and biological evaluation of carbohydrate functionalized cyclodextrins and liposomes for hepatocyte-specific targeting. Org Biomol Chem 2010, 8:4987-4996.
195. Singh A., Dilnawaz F., Sahoo S.K. Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. PLoS One 2011, 6:e26803.
196. Bielenberg D.R., Pettaway C.A., Takashima S., et al. Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 2006, 312:584-593.
197. Sugahara K.N., Teesalu T., Karmali P.P., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumours. Cancer Cell 2009, 16:510-520.
198. Kumar A., Ma H., Zhang X., et al. Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. Biomaterials 2012, 33:1180-1189.
199. Blanco E, Kessinger C.W., Sumer B.D., Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) 2009, 234:123-131.